Anki Malmborg Hager
Dr. Malmborg assumed the position as CEO in 2014. Before joining SenzaGen, Dr. Malmborg has worked for several small biotech companies, both as CEO and board member. She is the author of about 30 scientific papers and book chapters, and the inventor on a number of patents.
Marianne assumed the role as CFO in November 2016. Before joining SenzaGen Marianne has been working as Administrative and Financial Manager at the Department of Immunotechnology, Lund University.
Dr. Agemark assumed the role of Laboratory & Quality Manager at SenzaGen AB in the spring of 2015. She holds a PhD in Biochemistry with focus on the Aquaporins, a water transporting membrane protein family. Before joining SenzaGen she was a post doc at the Department of Immunotechnology, Lund University, where she developed antibodies against small target molecules relevant for the search of life on Mars.
Dr. Johansson has been working with genomics applications and development of in vitro assays since 2008. He is a co-developer of the GARD technology platform, which was first described in detail in his doctoral thesis. He assumed the role of Senior Scientist of SenzaGen in 2014.
Dr Smith is a European patent attorney at the firm of Potter Clarkson LLP, with expertise in biotech inventions including biomarker-based technologies. Together with his colleagues, Tom Harding and Lucy Mills, Steve advises SenzaGen in relation to all aspects of intellectual property rights and manages its growing IP portfolio. He became a consultant member of SenzaGen’s management team in early 2017.
BSC and PhD studies in Genetics. Peter has worked in the Life Science industry for more than 30 years, introducing numerous new products and brands in the marketplace. He was employed in BioInvent AB in the start up phase, had his own company for almost 20 years (GTF AB), and started Celltox AB that performed in vitro toxicology tests for customers. Most recently he was General Manager for Fisher Scientific in the Nordics.